Meitheal Acquires Rights of Nabriva’s Contepo, Expanding its Specialty Biopharmaceuticals Portfolio
Shots:
- Meitheal has entered into an asset purchase agreement with Nabriva to acquire Contepo's (fosfomycin for injection) rights, strengthening its specialty biopharmaceuticals portfolio
- As per the agreement, Meitheal secures North American rights of Contepo which includes its development & regulatory results, all related IP rights, technology & know-how. Nabriva will get payment upon closing plus the US net-sales-based royalty
- In addition, the US FDA’s decision on Contepo’s NDA for cUTI incl. acute pyelonephritis (submitted by Nabriva) is anticipated during H2’24. Meitheal will set up a commercial marketing & sales organization plus a medical science liaison (MSL) team for supporting clinicians
Ref: Meitheal | Image: Meitheal
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
